[{"id":"049acb0a-e716-4715-af42-f30f1499423c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05750290","created_at":"2023-03-01T15:02:17.647Z","updated_at":"2024-07-02T16:35:54.451Z","phase":"Phase 2","brief_title":"CKD-702 Plus Irinotecan in Gastric Cancer","source_id_and_acronym":"NCT05750290","lead_sponsor":"National Cancer Center, Korea","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR overexpression • MET overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR overexpression • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • CKD-702"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-03-01"}]